Abstracts Archive - Page 391 of 2425 - ACR Meeting Abstracts

Abstract Number: 1601 • ACR Convergence 2022
Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial
Michaela Koehm¹, Ann Christina Foldenauer², Tanja Rossmanith³, Herbert Kellner⁴, Uta Kiltz⁵, Juergen Rech⁶, Gerd Burmester⁷, David Kofler⁸, Jan Brandt-Juergens⁹, Stephanie Finzel¹⁰, Raoul Bergner¹¹, Maren Sieburg¹² and Frank Behrens¹³, ¹Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ³Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, Germany, ⁴Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶University Clinic Erlangen, Erlangen, Germany, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ¹⁰University of Freiburg, Freiburg, Germany, ¹¹Klinikum Ludwigshafen, Ludwigshafen, Germany, ¹²Rheumatologische Facharztpraxis, Magdeburg, Germany, ¹³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: Subgroup analysis from different clinical trials and real-world data suggest, that there are differences in baseline characteristics, clinical phenotypes, and treatment responses in female…
Abstract Number: 1593 • ACR Convergence 2022
Epidemiology and Outcomes of Infection-related Hospitalizations in Young Adults with SLE: Data from National Inpatient Sample
Rashmi Dhital¹, Monica Guma², Dilli Poudel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³Indiana Regional Medical Center, Indiana, PA, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Infection is the leading cause of hospitalization and mortality in SLE. Care of young adults (YA) with SLE is particularly challenging, with higher mortality…
Abstract Number: 1351 • ACR Convergence 2022
Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study
Cammie Young¹, Anna Montgomery², Catherine Nasrallah³, Lindsay Jacobsohn⁴, Jennifer Barton⁵, Sara Murray⁴, Jinoos Yazdany⁶ and Gabriela Schmajuk⁷, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³UCSF, San Francisco, ⁴University of California, San Francisco, San Francisco, CA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UCSF, San Francisco, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Shared decision making is a key component of a treat-to-target approach for the treatment of rheumatoid arthritis (RA). We created an EHR tool that…
Abstract Number: 1544 • ACR Convergence 2022
Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
Justine D'agostino¹, Valerie Devauchelle¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, Christophe Richez⁴, Marie Truchetet⁵, Daniel Wendling⁶, ERIC TOUSSIROT⁷, aleth Perdriger⁸, jacques-eric gottenberg⁹, Renaud FELTEN¹⁰, Bruno Fautrel¹¹, laurent chiche¹², Pascal HILLIQUIN¹³, Catherine Le Henaff¹⁴, Benjamin Dervieux¹⁵, Guillaume Direz¹⁶, Isabelle Chary-Valckenaere¹⁷, Divi CORNEC¹⁸, Dewi Guellec¹⁹, Thierry MARHADOUR²⁰, Aghiles Souki¹⁹, Emmanule Nowak¹⁹ and Alain Saraux²¹, ¹Université de Bretagne Occidentale, Brest, France, ²CHRU de Tours, Tours, France, ³LE MANS general hospital, LE MANS, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Bordeaux University Hospital, Bordeaux, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷CHU de Besançon, Besançon, France, ⁸Rennes University, Rennes, France, ⁹Strasbourg University Hospital, Strasbourg, France, ¹⁰Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹¹Pitié Salpêtrière Hospital, Paris, France, ¹²hopital europeen, Marseille, France, ¹³Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, ¹⁴Morlaix Hospital, Morlaix, France, ¹⁵Mulhouse Hospital, Mulhouse, France, ¹⁶Le Mans Hospital, Le Mans, France, ¹⁷Nancy University Hospital, Vandoeuvre, France, ¹⁸CHRU Brest, Brest, France, ¹⁹Brest University Hospital, Brest, France, ²⁰CHU Cavale Blanche, Brest, France, ²¹CHU Brest, Brest, France
Background/Purpose: Today, the only disease activity score developed specifically for polymylagia rheumatica is the PMR-AS. It is a composite index built as an algebraic sum…
Abstract Number: 1576 • ACR Convergence 2022
Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis
Umar Ghaffar¹, Hannah Langenfeld², Cynthia Crowson³, Tanaz Kermani⁴, Michelle Burke¹, Boyd Viers¹, Aaron Potretzke¹, Haraldur Bjarnason¹, Kenneth J. Warrington¹ and Matthew J. Koster¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴University of California Los Angeles, West Hills, CA
Background/Purpose: To evaluate the presentation features and outcomes of patients with chronic abdominal periaortitis in a large referral cohort. Methods: Using a proprietary medical text…
Abstract Number: 1589 • ACR Convergence 2022
Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis
Roy Fleischmann¹, Sharad Lakhanpal², WASSIM Saikali³, Daniel Alvarez⁴, Donna S Cox⁴, Claudia Ianos⁵, Karen Wang⁶ and Wuyan Zhang⁷, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³Rheumatology and Pulmonary Clinic, Beckley, WV, ⁴Pfizer, Inc, Collegeville, PA, ⁵Pfizer Zürich, Zürich, Switzerland, ⁶Pfizer, Inc, La Jolla, CA, ⁷Pfizer, Inc, Lake Forest, IL
Background/Purpose: PF-06410293 (ADL-afzb) is an adalimumab (ADL) biosimilar approved in the US, the EU, and 19 other countries. Biosimilarity of ADL-afzb with reference ADL (ADL-REF)…
Abstract Number: 1492 • ACR Convergence 2022
Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort
Murat Torgutalp¹, valeria Rios-Rodriguez², Ani Dilbaryan³, Fabian Proft⁴, Mikhail Protopopov⁵, Maryna Verba⁶, Judith Rademacher⁵, Hildrun Haibel¹, Joachim Sieper¹, Martin Rudwaleit⁷ and Denis Poddubnyy⁴, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, Moscow City Clinical Hospital, Moscow, Russia, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité-Universitätsmedizin Berlin, corporate member of Freie-Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: There are conflicting data regarding the effect of nonsteroidal anti-inflammatory drugs (NSAID) on radiographic spinal progression in axial spondyloarthritis (axSpA). The analysis of the…
Abstract Number: 1553 • ACR Convergence 2022
Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
Faustino Peron Filho¹, Andressa de Souza Moreira², Anna Larissa Janes² and Alexandre Wagner de Souza², ¹UNIFESP-EPM, Mogi das Cruzes, São Paulo, Brazil, ²UNIFESP-EPM, São Paulo, Brazil
Background/Purpose: Therapy for Takayasu arteritis (TAK) is based on the combination of high-dose glucocorticoids and immunosuppressive and/or biologic agents. Patients presenting severe disease manifestations are…
Abstract Number: 1600 • ACR Convergence 2022
The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Robert McLean², Taylor Blachley², Nicole Middaugh², Manish Mittal³, Jerry Clewell³, Sandra Ciecinski⁴ and Philip J Mease⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., Mettawa, IL, ⁵Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: While evidence in patients (pts) with RA suggests that switching to a therapy with a different mechanism of action (MOA) may be more effective…
Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 1585 • ACR Convergence 2022
Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Jeffrey Curtis¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹University of Alabama at Birmingham, Hoover, AL, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or…
Abstract Number: 1481 • ACR Convergence 2022
Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis
Sarah Lieber¹, Musarrat Nahid², Iris Navarro-Millan², Mangala Rajan², Sebastian Sattui³, Robyn Lipschultz¹, M. Carrington Reid² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with increased risk of dementia relative to age-matched comparators without systemic rheumatic disease (SRD) in non-US-based samples…
Abstract Number: 1596 • ACR Convergence 2022
The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk
Sarah Stoots¹, Joshua Baker¹ and Joan Von Feldt², ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Wilmington, DE
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at elevated cardiovascular risk. However, common risk calculators such as the atherosclerotic cardiovascular disease (ASCVD) risk estimator…
Abstract Number: 1564 • ACR Convergence 2022
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
Nuria Barroso-García¹, Belén Atienza-Mateo², Ivan Ferraz Amaro³, Diana Prieto-Peña², Ana De Vicente-Delmás⁴, Ricardo Blanco⁵ and Miguel Ángel González-Gay⁶, ¹Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital General Santa María del Puerto, Cádiz, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: To evaluate the efficacy of anti-TNF or anti-IL6 treatment in severe and refractory ocular involvement in patients with refractory cystoid macular edema (CME) due…
Abstract Number: 1495 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].